Skip to main content

Advertisement

Table 6 Summary of predicted resource use

From: Cost-effectiveness analysis for midostaurin versus standard of care in acute myeloid leukemia in the United Kingdom

Costs MIDO SOC Difference
Drug costs
 Induction and initiation £8242 £1747 £6495
 Consolidation £13,790 £2602 £11,188
 Monotherapy £36,021 £0 £36,021
 Secondary therapy costs £1354 £1531 − £177
Adverse events costs
 AEs induction costs £5293 £5557 − £264
 AEs consolidation costs £5198 £4659 £539
 AEs monotherapy costs £171 £0 £171
Routine care costs
 Routine care costs during drug treatment £9586 £8045 £1541
 Routine care after drug treatment £122,768 £132,429 − £9661
SCT cost £55,245 £46,172 £9073
Mortality costs £9656 £10,511 − £855
Total £267,325 £213,253 £54,072
  1. MIDO midostaurin, SOC standard of care, AE adverse event, SCT stem cell transplantation